What is HC Wainwright's Forecast for CGEM Q3 Earnings?

Key Points

• HC Wainwright raised its Q3 2026 EPS estimate for Cullinan Therapeutics to a loss of $0.86 per share, from a prior loss estimate of $0.90, while maintaining a “Buy” rating and $35 price target.
• Analyst sentiment is generally positive, with CGEM carrying a “Moderate Buy” consensus rating and an average price target of $33.71, despite some sell and hold ratings.
• Cullinan’s latest quarterly results missed expectations slightly, reporting a $0.81 per-share loss versus the $0.80 consensus estimate; institutional investors own 86.31% of the company.

Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) - Research analysts at HC Wainwright raised their Q3 2026 earnings estimates for shares of Cullinan Therapeutics in a research report issued on Friday, October 2nd. HC Wainwright analyst R. Burns now anticipates that the company will post earnings of ($0.86) per share for the quarter, up from their previous forecast of ($0.90). HC Wainwright has a "Buy" rating and a $35.00 price objective on the stock. The consensus estimate for Cullinan Therapeutics' current full-year earnings is ($3.08) per share. HC Wainwright also issued estimates for Cullinan Therapeutics' Q4 2026 earnings at ($0.89) EPS, FY2026 earnings at ($3.45) EPS, Q1 2027 earnings at ($0.44) EPS, Q2 2027 earnings at ($0.92) EPS, Q3 2027 earnings at ($0.93) EPS, Q4 2027 earnings at $0.39 EPS and FY2027 earnings at ($1.81) EPS.

CGEM has been the subject of a number of other research reports. Weiss Ratings reiterated a "sell (d-)" rating on shares of Cullinan Therapeutics in a research report on Wednesday, July 8th. TD Cowen upgraded Cullinan Therapeutics to a "strong-buy" rating in a research note on Monday, August 24th. Wall Street Zen lowered Cullinan Therapeutics from a "hold" rating to a "sell" rating in a research report on Sunday, September 13th. BTIG Research reaffirmed a "buy" rating and set a $40.00 price target on shares of Cullinan Therapeutics in a research note on Friday, September 25th. Finally, Wedbush lifted their price target on Cullinan Therapeutics from $39.00 to $42.00 and gave the company an "outperform" rating in a report on Thursday, August 13th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $33.71.

Cullinan Therapeutics Trading Up 3.4%

Shares of NASDAQ CGEM opened at $16.04 on Tuesday. Cullinan Therapeutics has a one year low of $5.71 and a one year high of $23.19. The business has a 50-day moving average price of $19.50 and a two-hundred day moving average price of $16.76. The firm has a market capitalization of $1.03 billion, a PE ratio of -5.17 and a beta of -0.05.

Cullinan Therapeutics (NASDAQ:CGEM - Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.80) by ($0.01).

Institutional Investors Weigh In On Cullinan Therapeutics

A number of large investors have recently added to or reduced their stakes in the stock. Integrated Wealth Concepts LLC bought a new position in Cullinan Therapeutics in the 2nd quarter worth $25,000. Seven Fleet Capital Management LP bought a new position in shares of Cullinan Therapeutics in the fourth quarter worth about $31,000. Caitong International Asset Management Co. Ltd lifted its position in shares of Cullinan Therapeutics by 181.9% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 4,680 shares of the company's stock worth $48,000 after purchasing an additional 3,020 shares during the last quarter. Allworth Financial LP bought a new stake in Cullinan Therapeutics during the 2nd quarter valued at approximately $53,000. Finally, Quantbot Technologies LP bought a new stake in Cullinan Therapeutics during the 2nd quarter valued at approximately $53,000. Institutional investors own 86.31% of the company's stock.

Insider Activity

In other news, insider Jennifer Michaelson sold 8,000 shares of the company's stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $21.57, for a total transaction of $172,560.00. Following the completion of the sale, the insider owned 158,844 shares in the company, valued at approximately $3,426,265.08. This represents a 4.79% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 8.60% of the company's stock.

About Cullinan Therapeutics

Cullinan Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing innovative medicines for cancer and autoimmune diseases. The company uses a portfolio-based approach to advance targeted therapies and immune-modulating treatments intended to address significant unmet medical needs.

Cullinan's pipeline includes zovoltamab brengitecan (CLN-978), an investigational CD19-directed T-cell engager being studied in B-cell malignancies and autoimmune conditions, and CLN-619, an investigational antibody designed to target MICA and MICB proteins and stimulate anti-tumor immune responses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.